Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Zacks Investment Management

Zacks Investment Management cut its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 64.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 43,073 shares of the medical equipment provider's stock after selling 76,599 shares during the quarter. Zacks Investment Management's holdings in Hologic were worth $3,509,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of HOLX. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the 3rd quarter worth approximately $25,000. Innealta Capital LLC acquired a new position in shares of Hologic during the 2nd quarter worth approximately $25,000. First Horizon Advisors Inc. raised its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares during the period. Sunbelt Securities Inc. acquired a new position in shares of Hologic during the 2nd quarter worth approximately $37,000. Finally, Cromwell Holdings LLC raised its stake in shares of Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after buying an additional 416 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Up 0.6 %

HOLX traded up $0.45 during mid-day trading on Monday, hitting $75.79. 2,326,179 shares of the stock were exchanged, compared to its average volume of 1,601,341. The firm's fifty day moving average is $79.81 and its two-hundred day moving average is $78.57. Hologic, Inc. has a 1-year low of $68.15 and a 1-year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a market cap of $17.20 billion, a PE ratio of 22.62, a PEG ratio of 2.37 and a beta of 0.96.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the company earned $0.89 EPS. Hologic's revenue was up 4.5% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HOLX shares. Raymond James upped their target price on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Citigroup cut Hologic from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. boosted their price target on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $89.91.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.75% of the stock is owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.